PVCT · Provectus Biopharmaceuticals, Inc.
$0.05
+0.00 (+0.00%)
At close · Oct 21
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The aforementioned factors indicate that management's plans do not alleviate the substantial doubt about the Company's ability to continue as a going concern for a period of one year from the issuance of these financial statements.”View the 10-Q filed Aug 13, 2026
Market Cap
$21.01M
Shares
420.28M
Volume · Oct 21
20.1K
Avg daily vol (3M)
123.61K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.05
Open$0.05
Day$0.05–0.05
52W close$0.04–0.08
Avg vol 30d75K
Short int801K · 0.2% float · 4.8d
Short vol60%
DataJan 2020–Oct 2026
Filing10-Q · Aug 13
Up next
filed Aug 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$460,185
Trailing 12 months
Net income (TTM)
−$4.73M
Trailing 12 months
Revenue growth YoY
-77.5%
Year over year
Operating margin
-1,575.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.0%
Year over year
Price change (1Y)
-33.5%
Trailing year
Short interest
0.2%
Latest settlement · 4.8 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 16.7 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−13%
below
Price vs 50-day avg
−10%
below
RSI (14)
41
neutral
MACD trend
Negative
52-week position
32%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−6%
trailing
6-month return
−12%
trailing
YTD return
−11%
this year
Relative strength
−20%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
2 of 4 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
0.19% of float · ▬ 0.0% MoM · 4.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
4 holders — near 3-yr low, contrarian setup
Squeeze score
37
low risk · 0–100
Fundamentals
EPS growth
0%
Y/Y
Free cash flow
$-3.4M
Quant / Vol
risk profile
Volatility
81%
annualized · 1-yr
Max drawdown
−49%
past year
ATR
8.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−13%
Bearish
Price vs 50-day avg
−10%
Bearish
RSI (14)
41
Neutral
MACD trend
Negative
Bearish
52-week position
32%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
No clear signal
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
2 of 4 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
0.19% of float · ▬ 0.0% MoM · 4.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
4 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $0
Now $0 · 32%
Range high $0
vs 200-day avg -13%
vs 50-day avg -10%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PVCT
this stock
Provectus Biopharmaceuticals, Inc.
|
$21.01M | -10.9% | -45.5% | — | 0.2% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.14B | +18.0% | +46.2% | 31.3 | 1.8% |
|
MRNA
Moderna, Inc.
|
$98.14B | +587.1% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.95B | +6.1% | +20.8% | 20.0 | 2.1% |
|
CSLLY
Csl Ltd
|
$66.22B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Holders
4
- % held
- 0.0%
- Reported
- 2 of 4
- Top holder
- HOME FEDERAL BANK OF TENN…
Held
Float
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PVCT | -0.2% | -5.7% | -12.5% | -12.6% | -10.9% |
| SPY | +0.5% | +0.7% | +7.6% | +1.4% | +13.4% |
| vs SPY | -0.7% | -6.4% | -20.0% | -14.0% | -24.3% |